LP-183 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-07-01
|
| Series: | Lupus Science and Medicine |